---
figid: PMC9675387__CNR2-5-e1720-g003
pmcid: PMC9675387
image_filename: CNR2-5-e1720-g003.jpg
figure_link: /pmc/articles/PMC9675387/figure/cnr21720-fig-0003/
number: FIGURE 3
figure_title: ''
caption: Epogen/Procrit and its biosimilars' mechanism of action. Once bound to the
  erythropoietin receptor, the JAKâ€“STAT signaling pathway is activated, leading to
  red blood cell survival, proliferation, and differentiation.
article_title: 'Oncology biosimilars: New developments and future directions.'
citation: Rinda Devi Bachu, et al. Cancer Rep (Hoboken). 2022 Nov;5(11):e1720.
year: '2022'

doi: 10.1002/cnr2.1720
journal_title: Cancer Reports
journal_nlm_ta: Cancer Rep (Hoboken)
publisher_name: John Wiley and Sons Inc.

keywords:
- bevacizumab
- biosimilars
- epoetins
- filgrastim
- new developments
- oncology
- pegfilgrastim
- rituximab

---
